|
|
|
| Effect of Zhizhu Kuanzhong Capsules on Hp eradication rate and recurrence rate in patients with gastric Hp infection |
| DAI Jinyu1 LIU Qiang2 SU Weixian1 SHI Zenghui1 ZHAO Junjing1 |
1.Department of Gastroenterology, Langfang People′s Hospital, Hebei Province, Langfang 065000, China;
2.Department of Emergency, Langfang Hospital of Traditional Chinese Medicine, Hebei Province, Langfang 065000, China |
|
|
|
Abstract Objective To investigate the effect of Zhizhu Kuanzhong Capsules on Helicobacter pylori (Hp) eradication rate and recurrence rate in patients with gastric Hp infection. Methods From January 2015 to January 2017, in Langfang People′s Hospital, 300 patients with gastric Hp infection were selected, they were divided into the control group and the treatment group by rondom number table method, with 150 cases in each group. The control group was given quadruple therapy, the treatment group was given Zhizhu Kuanzhong Capsules combined with quadruple therapy. The two groups were treated for 2 weeks. The Hp eradication rates of two groups 1 month after discontinuation were compared, the Hp recurrence rates of the two groups 12 months after discontinuation were compared, the serum CRP, PGⅠ, PGⅡ of two groups before treatment and 1 month after discontinuation were compared. The conditions of adverse reactions of the two groups during the treatment were recorded and compared. Results The Hp eradication rate of the treatment group was higher than that of the control group, the difference was statistically significant (P ＜ 0.05). The Hp recurrence rate of the treatment group 12 months after discontinuation was significantly lower than that of the control group, the difference was statistically significant (P ＜ 0.05). The levels of serum CRP, PGⅡ of the two groups 1 month after discontinuation were significantly lower than those before treatment, the levels of serum PGⅠ of the two groups 1 month after discontinuation were significantly higher than those before treatment, and the improvement of serum CRP, PGⅠ, PGⅡ levels of the treatment group was significantly better than those of the control group, the differences were statistically significant (P ＜ 0.05). During treatment, the rate of adverse reactions between the two groups had no significant difference (P ＞ 0.05). Conclusion Zhizhu Kuanzhong Capsules combined with quadruple therapy in patients with gastric Hp infection has high Hp eradication rate, low recurrence rate, which can improve the inflammation of the gastric mucosa, with good safety, and it is worthy of clinical application.
|
|
|
|
|
|
[1] 金夏，冀子中，韩丰，等.幽门螺杆菌感染与胃部疾病关系性分析[J].当代医学，2018，24（16）：108-109.
[2] 杨丽清，周宇.我国幽门螺杆菌感染现状和治疗进展[J].临床医药文献电子杂志，2017，4（90）：17808-17809.
[3] 刘洪英.幽门螺杆菌感染的治疗现状及进展[J].中国处方药，2018，16（4）：15-17.
[4] 宋丹丹，李静.抗幽门螺杆菌治疗的研究现状[J].锦州医科大学学报，2017，38（5）：108-112.
[5] 祝焕杰，莫红梅，许书维，等.幽门螺杆菌的认识及诊疗新进展[J].光明中医，2018，33（3）：449-452.
[6] 张风宾，吴忱思，王滢滢，等.枳术宽中胶囊治疗功能性消化不良临床分析[J].河北中医，2016，38（9）：1297-1337.
[7] 宗燕.幽门螺杆菌感染与胃癌前病变、胃癌的关系分析[J].影像研究与医学应用，2018，2（10）：12-13.
[8] 张斌忠，何春华，王胤达，等.幽门螺杆菌与胃癌细胞多药耐药的关系及机制研究[J].中华医院感染学杂志，2018， 28（7）：975-978.
[9] 陈娇娥，吴建胜，黎宏章，等.含多西环素、阿莫西林四联方案根除幽门螺杆菌的疗效观察[J].浙江医学，2018，40（6）：596-599.
[10] 彭洪亮.中药治疗幽门螺杆菌感染性胃病的疗效分析[J].中医临床研究，2018，10（2）：49-50.
[11] 刘华梅.小剂量奥美拉唑联合枳术宽中胶囊治疗功能性消化不良的效果分析[J].北方药学，2015，12（1）：54.
[12] 陈秒旬，林海雄，陈瑞芳.枳术宽中胶囊治疗功能性消化不良临床观察的系统评价与Meta分析[J].中国中医药现代远程教育，2017，15（22）：154-158.
[13] 李依洁，苏晓兰，史海霞，等.含枳术宽中胶囊的四联疗法治疗单纯幽门螺杆菌感染性胃炎的临床回顾性研究[J].实用药物与临床，2017，20（2）：151-153.
[14] 杨君寅，李玉梅，朱建华，等.瑞巴派特片联合枳术宽中胶囊治疗慢性胃炎疗效观察[J].新中医，2017，49（5）：44-46.
[15] 汤国军，童駸，胡丛岗，等.胃癌患者幽门螺杆菌感染与IL-2及IL-8的相关性研究[J].中华医院感染学杂志，2017，27（22）：5133-5136.
[16] 于杰.中药辅助治疗幽门螺杆菌阳性消化性溃疡的疗效观察[J].中国医药科学，2017，7（11）：74-76.
[17] 毕月，罗微，谷海瀛.幽门螺杆菌致病因子作用机制研究概述[J].基础医学与临床，2018，38（5）：713-716.
[18] 马健，孟欣颖，王涛，等.慢性活动性胃炎患者血清IL-6、TGF-β1及IL-17的水平与幽门螺杆菌的关系及临床意义[J].中华临床医师杂志：电子版，2012，6（11）：2908-2910.
[19] 胡冰，王鼎峰.HPLC测定枳术宽中胶囊中4种有效成分[J].中国现代应用药学，2015，32（3）：335-339.
[20] 张晓丹.三联疗法联合中药对胃溃疡患者血清炎症因子的影响[J].中国医药科学，2017，7（2）：53-55.
[21] 施凌鹤，贡联兵.枳术宽中胶囊的临床应用评价[J].中国医院用药评价与分析，2013，13（4）：305-307.
[22] 李多，王锐，于永强，等.雷贝拉唑、阿莫西林、克拉霉素联合枳术宽中胶囊治疗老年幽门螺杆菌阳性慢性萎缩性胃炎[J].山东医药，2018，58（3）：78-80. |
|
|
|
